Document -
Vironova AB (publ) granted new US-patent for an anti-herpes compound.
With the approval of a US herpes patent, Vironova AB (publ) is now moving forward with the development of an effective topical medical therapy for herpes cold sores in compliance with the US Food and Drug Administration (FDA) regulations.
- License:
- Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
- File format:
